80099-88-3

Basic information

• Product Name: (2-chloropyridin-4-yl)(phenyl)methanone
• Synonyms: (2-chloropyridin-4-yl)(phenyl)methanone
• CAS NO: 80099-88-3
• Molecular Weight: 217.655
• Mol File: 80099-88-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (2-chloropyridin-4-yl)(phenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2-chloropyridin-4-yl)(phenyl)methanone(80099-88-3)
• EPA Substance Registry System: (2-chloropyridin-4-yl)(phenyl)methanone(80099-88-3)

Safety Data

• Hazardous Substances Data: 80099-88-3(Hazardous Substances Data)

Upstream product

• 65287-34-5 2-chloropyridine-4-carbonyl chloride 
• 71-43-2 benzene 
• 1227940-97-7 2-chloro-4-pyridylzinc bromide 
• 98-88-4 benzoyl chloride 
• 73583-37-6 2-chloro-4-bromopyridine 
• 14178-29-1 (1-oxidopyridin-4-yl) (phenyl)methanone 
• 7259-53-2 4-benzylpyridine N-oxide 
• 33252-30-1 2-chloro-4-pyridinenitrile 
• 591-50-4 iodobenzene 
• 2942-59-8 2-chloronicotinic acid 

Downstream Products

• 332133-57-0 4-benzoyl-2-methoxypyridine 
• 332133-95-6 4-(a-hydroxybenzyl)-2-(2-methoxyethoxy)pyridine 
• 332133-61-6 4-benzyl-5-bromo-2-methoxypyridine 
• 332133-62-7 4-benzyl-5-bromo-2-hydroxypyridine 
• 332133-60-5 4-benzyl-2-methoxypyridine 

Relevant articles and documents

EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS

The present invention relates to novel compounds of formula I, or pharmaceutically acceptable salts, solvates or stereoisomers thereof, also to a pharmaceutical composition, a method for inhibiting biological activity of epidermal growth factor receptor (

Preparation 2-substituted-4-pyridylzinc bromides via direct insertion of active zinc and their coupling reactions

-

Novel aryl- and heteroarylpiperazines

Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.